In collaborations with J. Cook, University of Wisconsin, USA, and Robert Dodd, CNRS, Gif sur Yvette, France, we are aiming to develop GABAA receptor subtype-selective drugs. Recent studies in our laboratory identified compounds, such as PWZ-029, with a partial inverse agonist effect on α5 subunit-containing GABAA receptors, that could have memory enhancing properties (Savic et al. 2008, Brain Res. 1208: 150). Other compounds investigated (not shown) exhibit a significant selectivity for α2 and α3 subunit-containing receptors, that could have application as anxiolytics or as drugs against neuropathic pain.
Researchers involved:
Joachim Ramerstorfer
Sieghart (2006) in "Adv Pharmacol 54" (Enna) p 231 pdf
Khom et al (2006) Mol Pharmacol 69:640 pdf
Clayton et al (2007) Curr Top Med Chem 14:2755 pdf
Furtmüller et al. (2008) Eur J Pharmacol 591:142 pdf
Harris et al. (2008) J Med Chem 51:3788 pdf
Savic et al (2008) Neuropsychopharm 33:332 pdf
Han et al (2008) Bioorg Med Chem 16:8853 pdf
Savic et al (2008) Brain Res 1208:150 pdf
Rivas et al (2009) J Med Chem 52:1795 pdf
Savic et al (2010) Progr Neuro Psychopharm Biol Psy 34:376 pdf
Ramerstorfer et al (2010) Eur J Pharmacol 636:18
Ramerstorfer et al (2011) J Neurosci 31:870
Sieghart et al (2012) Brit J Pharmacol in press
Seeger et al (2012) Biochem Pharmacol in press
